Updated:
Synergenics LLC
Synergenics LLC is a single-family office for the Rutter family, investing in early-stage biotech via a consortium model.
Synergenics LLC
Synergenics LLC was founded by William J. Rutter, the UCSF biochemist who co-founded Chiron Corporation in 1981. Rutter passed away in July 2025, leaving the firm professionally managed by a four-person team led by CEO Sebastián Bernales and CIO Francisco Dopazo. The firm operates as a consortium of commonly owned but independently managed biotech companies. It backs early-stage ventures across biotechnology, diagnostics, therapeutics, and synthetic biology. Confirmed portfolio companies include Ansa Biotechnology, Bluejay Therapeutics, Centaurus, Pyxis Oncology, and Metagenomi (Nasdaq: MGX) — the latter co-founded by Bernales. The firm's geographic footprint spans San Francisco, Shanghai, Herzliya, St. Louis, and New York, though the sole disclosed office is in San Francisco. Synergenics runs a lean team of four professionals. Beyond direct portfolio investments, Bernales serves as a General Partner at Humboldt Fund, a New York–based venture capital firm that appears in the Synergenics portfolio as an investment vehicle. The firm operates without external AUM disclosure, consistent with a single-family-office structure. No recent operational events (last 24 months) are publicly available. The consortium model is Synergenics' structural differentiator: portfolio companies retain scientific autonomy while sharing operational infrastructure, reducing burn and increasing capital efficiency. This hybrid approach — between a family office and an incubator — is rare among single-family offices and directly informed by Rutter's biotech founding experience.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Francisco
Corporate office
1700 Montgomery St., Suite 108, San Francisco, CA 94111, United States
Principals
Sebastián Bernales
Chief Executive Officer
Francisco Dopazo
Chief Investment Officer
William J. Rutter
Founder and Chairman (in memoriam)
Sector focus
Frequently asked questions
Who runs investment decisions at Synergenics?
Investment decisions are overseen by CEO Sebastián Bernales and CIO Francisco Dopazo. Bernales also serves as a board member for multiple portfolio companies and as a GP at Humboldt Fund (per firm website).
Is Synergenics structured as a single family office or does it operate more like a venture firm?
Synergenics is a single-family office for Bill Rutter and his foundation, but it operates a consortium of independently managed biotech companies. This gives it a hybrid posture akin to an incubator or venture builder, distinct from a traditional venture capital firm (per firm website).
Does Synergenics participate in fund commitments or only direct deals?
Synergenics makes direct investments in its portfolio companies. Its CEO also participates in outside funds: Sebastián Bernales is a General Partner at Humboldt Fund, which invests in early-stage biotech and synthetic biology (per firm website).
What investment stages does Synergenics typically target?
Synergenics focuses on early-stage life sciences ventures, including clinical-stage biopharma, platform biotech, and diagnostic startups. Portfolio companies range from preclinical to clinical-stage (per firm website).
Which sectors does Synergenics explicitly focus on?
The firm concentrates exclusively on life sciences and healthcare, including biotechnology, therapeutics, diagnostics, synthetic biology, and digital health. It does not appear to invest outside these sectors (per firm website).
Where does the underlying wealth come from?
Wealth originates from William J. Rutter, co-founder of Chiron Corporation, a pioneering biotech firm that developed the first recombinant Hepatitis B vaccine and helped sequence the HIV and Hepatitis C genomes (per firm website).
Does Synergenics maintain philanthropic structures, and how are they separated?
The firm describes itself as representing Bill Rutter and his foundation, indicating a philanthropic arm is linked to the family office. However, no separate foundation name or structure is publicly disclosed (per firm website).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: